{
  "url": "https://openlegislation.uk/eu-regulation-2014-1154/annex",
  "json_url": "https://openlegislation.uk/eu-regulation-2014-1154/annex.json",
  "legislation": "eur/2014/1154",
  "legislation_title": "Commission Regulation (EU) No 1154/2014 of 29 October 2014 refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children's development and health (Text with EEA relevance)",
  "legislation_url": "https://openlegislation.uk/eu-regulation-2014-1154",
  "path": "annex",
  "kind": "annex",
  "number": null,
  "heading": "REJECTED HEALTH CLAIMS",
  "text": "Application — Relevant provisions of Regulation (EC) No 1924/2006\nNutrient, substance, food or food category\nClaim\nEFSA opinion reference\nArticle 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data\nZinc\nPrevents bad breath by neutralising of volatile sulphur compounds (VSC) in the mouth and oral cavity.\nQ-2010-01092\nArticle 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data\nYestimun®\nDaily administration of Yestimun® helps to maintain the body's defence against pathogens.\nQ-2012-00761\nArticle 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data\nTransitech®\nImproves transit and durably regulates it.\nQ-2013-00087\nArticle 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data\nBimuno® GOS\nRegular daily consumption of 1,37 g galacto-oligosaccharides from Bimuno® may reduce abdominal discomfort.\nQ-2012-01007\nArticle 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data\nLactobacillus rhamnosus GG\nLactobacillus rhamnosus GG for maintaining normal defecation during oral antibiotic treatment.\nQ-2013-00015\nArticle 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data\nVeriSol®P\nCharacteristic collagen peptide mixture (collagen hydrolysate) having a beneficial physiological effect on the maintenance of skin health, as indicated by an increased skin elasticity and a reduction of wrinkles volume, by contributing to a normal collagen and elastin synthesis.\nQ-2012-00839\nArticle 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data\nProanthocyanidins in Urell®\nProanthocyanidins from Urell® contribute to support defence against bacterial pathogens in the lower urinary tract\nQ-2012-00700\nArticle 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data\nPreservation®\nImproves the physiological response to stress by accelerating the appearance of heat shock proteins (HSPs) and maintains an effective level of HSPs to ensure that the organism is primed should the cell encounter further stress.\nQ-2013-00021",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/eur/2014/1154/annex",
    "retrieved_at": "2026-11-01T14:47:11.161499+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}